Desflurane

Desflurane

Beijing Tiantan HospitalSmall moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 95/ 100

Competitive context

5 Active assets in the Desflurane cohort.

Asset / Sponsor	Phase	Rating
Remimazolam Seoul National University Bundang Hospital	Phase 4	BB
RAMIFENTANYL Beijing Tiantan Hospital	N/A	D
CISATRACURIUM ION Beijing Tiantan Hospital	N/A	D
SUFENTANIL CITRATE Beijing Tiantan Hospital	N/A	D
PROPOFOL Beijing Tiantan Hospital	N/A	D

Same molecule, other indications

Desflurane is also rated in:

colorectal cancerDormant

BBB

Indicative ·

74 / 100

Circulating Tumor CellsDormant

BBB

Indicative ·

74 / 100

Anesthesia, LocalDormant

BBB

Indicative ·

73 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.